Functional genomics and the development of pathogenesis-targeted therapies for Kaposi's sarcoma

Pharmacogenomics

Volumn 6, Issue 3, 2005, Pages 235-244

  McAllister, Shane C ^a   Früh, Klaus ^a   Moses, Ashlee V ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b NONE   (United States)

Author keywords

c Kit; Gleevec ; HHV 8; HO 1; Kaposi's sarcoma; KSHV; Mesoporphyrins

Indexed keywords

ALITRETINOIN; DAUNORUBICIN; DOXORUBICIN; FLICE INHIBITORY PROTEIN; FOSCARNET; GANCICLOVIR; HEME OXYGENASE 1; IMATINIB; LATENCY ASSOCIATED NUCLEAR ANTIGEN; MESOPORPHYRIN; MESOPORPHYRIN CHROMIUM; PACLITAXEL; STEM CELL FACTOR; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AFRICA; CLINICAL FEATURE; CLINICAL TRIAL; DIARRHEA; DIGESTIVE SYSTEM CANCER; DRUG COST; DRUG TARGETING; FUNCTIONAL GENOMICS; HEALTH CARE ACCESS; HEALTH ECONOMICS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN HERPESVIRUS 8; KAPOSI SARCOMA; NONHUMAN; PATHOGENESIS; REVIEW; SKIN CANCER; VIRUS INFECTION;

ANTINEOPLASTIC AGENTS; GENOMICS; HEME OXYGENASE-1; HERPESVIRUS 8, HUMAN; HUMANS; MESOPORPHYRINS; MODELS, BIOLOGICAL; OLIGONUCLEOTIDES, ANTISENSE; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; SARCOMA, KAPOSI;

HERPESVIRIDAE; HERPESVIRUS 8; HUMAN HERPESVIRUS 8;

EID: 18044367899     PISSN: 14622416     EISSN: None     Source Type: Journal    
DOI: 10.1517/14622416.6.3.235     Document Type: Review

References (110)

1. Braun M: Classics in oncology. Idiopathic multiple pigmented sarcoma of the skin by Kaposi. CA Cancer J. Clin. 32, 340-347 (1982).
2. Friedman-Kien AE, Laubenstein LJ, Rubinstein P et al.: Disseminated Kaposi's sarcoma in homosexual men. Ann. Intern. Med. 96, 693-700 (1982).
3. Dourmishev LA, Dourmishev AL, Palmeri D, Schwartz RA, Lukac DM: Molecular genetics of Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8) epidemiology and pathogenesis. Microbiol. Mol. Biol. Rev. 67, 175-212 (2003).
4. Flaitz CM, Nichols CM, Hicks MJ: Herpesviridae-associated persistent mucocutaneous ulcers in acquired immunodeficiency syndrome. A clinicopathologic study. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 81, 433-441 (1996).
5. Chang Y, E Cesarman, Pessin MS et al.: Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma [see comments]. Science 266, 1865-1869 (1994).
6. Boshoff C, Schulz TF, Kennedy M et al.: Kaposi's sarcoma-associated herpesvirus infects endothelial and spindle cells. Nat. Med. 1, 1274-1278 (1995).
7. Soulier J, Grollet L, Oksenhendler E et al.: Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood 86, 1276-1280 (1995).
8. Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM: Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N. Engl. J. Med. 332, 1186-91 (1995).
9. Cesarman E, Nador RG, Aozasa K, Delsol G, Said JW, Knowles DM: Kaposi's sarcoma-associated herpesvirus in non-AIDS related lymphomas occurring in body cavities. Am. J. Pathol. 149, 53-57 (1996).
10. Russo JJ, Bohenzky RA, Chien MC et al.: Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8). Proc. Natl Acad. Sci. USA 93, 14862-14867 (1996).
11. Sarid R, Olsen SJ, Moore PS: Kaposi's sarcoma-associated herpesvirus: epidemiology, virology, and molecular biology. Adv. Virus. Res. 52, 139-232 (1999).
12. Davis MA, Sturzl MA, Blasig C et al.: Expression of human herpesvirus 8-encoded cyclin D in Kaposi's sarcoma spindle cells. J. Natl Cancer Inst. 89, 1868-1874 (1997).
13. Dupin NC, Fisher, Kellam P et al.: Distribution of human herpesvirus-8 latently infected cells in Kaposi's sarcoma, multicentric Castleman's disease, and primary effusion lymphoma. Proc. Natl Acad. Sci. USA. 96, 4546-4551 (1999).
14. Sturzl M, Blasig C, Schreier A et al.: Expression of HHV-8 latency-associated T0.7 RNA in spindle cells and endothelial cells of AIDS-associated, classical and African Kaposi's sarcoma. Int. J. Cancer 72, 68-71 (1997).
15. Sadler R, Wu L, Forghani B et al.: A complex translational program generates multiple novel proteins from the latently expressed kaposin (K12) locus of Kaposi's sarcoma-associated herpesvirus. J. Virol. 73, 5722-5730 (1999).
16. Rivas C, Thlick AE, Parravicini C, Moore PS, Chang Y: Kaposi's sarcoma-associated herpesvirus LANA2 is a B-cell-specific latent viral protein that inhibits p53. J. Virol. 75, 429-438 (2001).
17. Djerbi M, Screpanti V, Catrina AI, Bogen B, Biberfeld P, Grandien A: The inhibitor of death receptor signaling, FLICE-inhibitory protein defines a new class of tumor progression factors. J. Exp. Med. 190, 1025-1032 (1999).
18. Thome M, Schneider P, Hofmann K et al.: Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature 386, 517-521 (1997).
19. Liu L, Eby MT, Rathore N, Sinha SK, Kumar A, Chaudhary PM: The human herpes virus 8-encoded viral FLICE inhibitory protein physically associates with and persistently activates the IκB kinase complex. J. Biol. Chem. 277, 13745-13751 (2002).
20. Matta H, Chaudhary PM: Activation of alternative NF-κB pathway by human herpes virus 8-encoded Fas-associated death domain-like IL-1 β-converting enzyme inhibitory protein (vFLIP). Proc. Natl Acad. Sci. USA 101, 9399-9404 (2004).
21. Guasparri I, Keller SA, Cesarman E: KSHV vFLIP is essential for the survival of infected lymphoma cells. J. Exp. Med. 199, 993-1003 (2004).
22. Brown HJ, Song MJ, Deng H, Wu TT, Cheng G, Sun R: NF-κB inhibits γ-herpesvirus lyric replication. J. Virol. 77, 8532-8540 (2003).
23. Chang Y, Moore PS, Talbor SJ et al.: Cyclin encoded by KS herpesvirus. Nature 382, 410 (1996)
24. Child ES, Mann DJ: Novel properties of the cyclin encoded by human herpesvirus 8 that facilitate exit from quiescence. Oncogene 20, 3311-3322 (2001).
25. 1. J. Virol. 71, 4193-4198 (1996).
26. Verschuren EW, Klefstrom J, Evan GI, Jones N: The oncogenic potential of Kaposi's sarcoma-associated herpesvirus cyclin is exposed by p53 loss in vitro and in vivo. Cancer Cell 2, 229-241 (2002).
27. Friborg J Jr, Kong W, Hottiger MO, Nabel GJ: p53 inhibition by the LANA protein of KSHV protects against cell death. Nature 402, 889-894 (1999).
28. Radkov SA, Kellam P, Boshoff C: The latent nuclear antigen of Kaposi sarcoma-associated herpesvirus targets the retinoblastoma-E2F pathway and with the oncogene Hras transforms primary rat cells. Nat. Med. 6, 1121-1127 (2000).
29. Ballestas ME, Kaye KM: Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen 1 mediates episome persistence through cis-acting terminal repeat (TR) sequence and specifically binds TR DNA. J. Virol. 75, 3250-3258 (2001).
30. Li H, Komatsu T, Dezube BJ, Kaye KM: The Kaposi's sarcoma-associated herpesvirus K12 transcript from a primary effusion lymphoma contains complex repeat elements, is spliced, and initiates from a novel promoter. J. Virol. 76, 11880-11888 (2002).
31. Muralidhar S, Pumfrey AM, Hassani M et al.: Identification of kaposin (open reading frame K12) as a human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus) transforming gene. J. Virol. 72, 4980-4988 (1998).
32. Muralidhar S, Veytsmann G, Chandran B, Ablashi D, Doniger J, Rosenthal LJ: Characterization of the human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus) oncogene, kaposin (ORF K12). J. Clin. Virol. 16, 203-213 (2000).
33. McCormick C, Ganem D: The kaposin B protein of KSHV activates the p38/MK2 pathway and stabilizes cytokine mRNAs. Science 307, 739-741 (2005).
34. Bais C, Santomasso B, Coso O et al.: G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator. Nature 391, 86-89 (1998).
35. Cesarman E, Nador RG, Bai F et al.: Kaposi's sarcoma-associated herpesvirus contains G protein-coupled receptor and cyclin D homologs which are expressed in Kaposi's sarcoma and malignant lymphoma. J. Virol. 70, 8218-8223 (1996).
36. Moore PS, Boshoff C, Weiss RA, Chang Y: Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV. Science 274, 1739-1744 (1996).
37. Cannon J, Hamzeh F, Moore S, Nicholas J, Ambinder R: Human herpesvirus 8-encoded thymidine kinase and phosphotransferase homologues confer sensitivity to ganciclovir. J. Virol. 73, 4786-4793 (1999).
38. Guo HG, Browning P, Nicholas J et al.: Characterization of a chemokine receptor-related gene in human herpesvirus 8 and its expression in Kaposi's sarcoma. Virology 228, 371-378 (1997).
39. Staskus KA, Sun R, Miller G et al.: Cellular tropism and viral interleukin-6 expression distinguish human herpesvirus 8 involvement in Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease. J. Virol. 73, 4181-4187 (1999).
40. Montaner S, Sodhi A, Molinolo A et al.: Endothelial infection with KSHV genes in vivo reveals that vGPCR initiates Kaposi's sarcomagenesis and can promote the tumorigenic potential of viral latent genes. Cancer Cell 3, 23-36 (2003).
41. Hayward GS: Initiation of angiogenic Kaposi's sarcoma lesions. Cancer Cell 3, 1-3 (2003).
42. Naranatt PP, Krishnan HH, Svojanovsky SR, Bloomer C, Mathur S, Chandran B: Host gene induction and transcriptional reprogramming in Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8)-infected endothelial, fibroblast, B cells: insights into modulation events early during infection. Cancer Res. 64, 72-84 (2004).
43. Glesby MJ, Hoover DR, Weng S et al.: Use of antiherpes drugs and the risk of Kaposi's sarcoma: data from the Multicenter AIDS Cohort Study. J. Infect. Dis. 173, 1477-1480 (1996).
44. Martin DF, Kuppermann BD, Wolitz RA, Palestine AG, Li H, Robinson CA: Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group. N. Engl. J. Med. 340, 1063-1070 (1999).
45. Mocroft A, Youle M, Gazzard B, Morcinek J, Halai R, Phillips AN: Anti-herpesvirus treatment and risk of Kaposi's sarcoma in HIV infection. Royal Free/Chelsea and Westminster Hospitals Collaborative Group. AIDS 10, 1101-1105 (1996)
46. Dezube BJ, Pantanowitz L, Aboulafia DM: Management of AIDS-related Kaposi sarcoma: advances in target discovery and treatment. AIDS Read. 14, 236-238, 243-244, 251-253 (2004).
47. Chak LY, Gill PS, Levine AM, Meyer PR, Anselmo JA, Petrovich Z: Radiation therapy for acquired immunodeficiency syndrome-related Kaposi's sarcoma. J. Clin. Oncol. 6, 863-867 (1988).
48. Nobler MP, Leddy ME, Huh SH: The impact of palliative irradiation on the management of patients with acquired immune deficiency syndrome. J. Clin. Oncol. 5, 107-112 (1987).
49. Walmsley S, Northfelt DW, Melosky B, Conant M, Friedman-Kien AE, Wagner B: Treatment of AIDS-related cutaneous Kaposi's sarcoma with topical alitretinoin (9-cis-retinoic acid) gel. Panretin Gel North American Study Group. J. Acquir. Immune Defic. Syndr. 22, 235-246 (1999).
50. Groopman JE, Gottlieb MS, Gottlieb J et al.: Recombinant α-2 interferon therapy for Kaposi's sarcoma associated with the acquired immunodeficiency syndrome. Ann. Intern. Med. 100, 671-676 (1984).
51. Cheung TW: AIDS-related cancer in the era of highly active antiretroviral therapy (HAART): a model of the interplay of the immune system, virus, and cancer "On the offensive - the Trojan Horse is being destroyed"-Part B: Malignant lymphoma. Cancer Invest. 22, 787-798 (2004).
52. Aversa SM, Cattelan AM, Salvagno L et al.: Treatments of AIDS-related Kaposi's sarcoma. Crit. Rev. Oncol. Hematol. 53, 253-265 (2005).
53. Cattelan AM, Trevenzoli M, Aversa SM: Novel pharmacological therapies for the treatment of AIDS-related Kaposi's sarcoma. Expert Opin. Investig. Drugs 13, 501-513 (2004).
54. Cheung TW: AIDS-related cancer in the era of highly active antiretroviral therapy (HAART): a model of the interplay of the immune system, virus, and cancer. "On the offensive - the Trojan Horse is being destroyed"-Part A: Kaposi's sarcoma. Cancer Invest. 22, 774-786 (2004).
55. Bogner JR, Kronawitter U, Rolinski B, Truebenbach K, Goebel FD: Liposomal doxorubicin in the treatment of advanced AIDS-related Kaposi sarcoma. J. Acquir. Immune Defic. Syndr. 7, 463-468 (1994).
56. Harrison M, Tomlinson D, Stewart S: Liposomal-entrapped doxorubicin: an active agent in AIDS-related Kaposi's sarcoma. J. Clin. Oncol. 13, 914-920 (1995).
57. Northfelt DW, Dezube BJ, Thommes JA et al.: Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized Phase III clinical trial. J. Clin. Oncol. 16, 2445-2451 (1998).
58. Saville MW, Lietzau J, Pluda JM et al.: Treatment of HIV-associated Kaposi's sarcoma with paclitaxel. Lancet 346, 26-28 (1995).
59. Sgadari C, Toschi E, Palladino C et al.: Mechanism of paclitaxel activity in Kaposi's sarcoma. J. Immunol. 165, 509-517 (2000).
60. Welles L, Saville MW, Lietzau J et al.: Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi's sarcoma. J. Clin. Oncol. 16, 1112-1121 (1998).
61. Doutrelepont JM, De Pauw L, Gruber SA et al.: Renal transplantation exposes patients with previous Kaposi's sarcoma to a high risk of recurrence. Transplantation 62, 463-466 (1996).
62. Penn I: Kaposi's sarcoma in organ transplant recipients: report of 20 cases. Transplantation 27, 8-11 (1979).
63. Dedicoat M, Vaithilingum M, Newton R: Treatment of Kaposi's sarcoma in HIV-1 infected individuals with emphasis on resource poor settings. Cochrane Database Syst. Rev. CD003256 (2003).
64. Aluigi MG, Albini A, Carlone S et al.: KSHV sequences in biopsies and cultured spindle cells of epidemic, iatrogenic and Mediterranean forms of Kaposi's sarcoma. Res. Virol. 147, 267-275 (1996).
65. Beckstead JH, Wood GS, Fletcher V: Evidence for the origin of Kaposi's sarcoma from lymphatic endothelium. Am. J. Pathol. 119, 294-300 (1985).
66. Roth WK, Werner S, Risau W, Remberger K, Hofschneider PH: Cultured, AIDS-related Kaposi's sarcoma cells express endothelial cell markers and are weakly malignant in vitro. Int. J. Cancer 42, 767-773 (1988).
67. Rutgers JL, Wieczorek R, Bonetti F et al.: The expression of endothelial cell surface antigens by AIDS-associated Kaposi's sarcoma. Evidence for a vascular endothelial cell origin. Am. J. Pathol. 122, 493-499 (1986).
68. Scully PA, Steinman HK, Kennedy C, Trueblood K, Frisman DM, Voland JR: AIDS-related Kaposi's sarcoma displays differential expression of endothelial surface antigens. Am. J. Pathol. 130, 244-251 (1988).
69. Li JJ, Huang YQ, Cockerell CJ, Friedman-Kien AE: Localization of human herpes-like virus type 8 in vascular endothelial cells and perivascular spindle-shaped cells of Kaposi's sarcoma lesions by in situ hybridization. Am. J. Pathol. 148, 1741-1748 (1996).
70. Staskus KA, Zhong W, Gebhard K et al.: Kaposi's sarcoma-associated herpesvirus gene expression in endothelial (spindle) tumor cells. J. Virol. 71, 715-719 (1997).
71. Ciufo DM, Cannon JS, Poole LJ et al.: Spindle cell conversion by Kaposi's sarcoma-associated herpesvirus: formation of colonies and plaques with mixed lytic and latent gene expression in infected primary dermal microvascular endothelial cell cultures. J. Virol. 75, 5614-5626 (2001).
72. Flore O, Rafii S, Ely S, O'Leary JJ, Hyjek EM, Cesarman E: Transformation of primary human endothelial cells by Kaposi's sarcoma- associated herpesvirus. Nature 394, 588-592 (1998).
73. Lagunoff M, Bechtel J, Venetsanakos E et al.: De novo infection and serial transmission of Kaposi's sarcoma-associated herpesvirus in cultured endothelial cells. J. Virol. 76, 2440-2448 (2002).
74. Moses AV, Fish KN, Ruhl R et al.: Long-term infection and transformation of dermal microvascular endothelial cells by human herpesvirus 8. J. Virol. 73, 6892-6902 (1999).
75. Ambroziak JA, Blackbourn DJ, Herndier BG et al.: Herpes-like sequences in HIV-infected and uninfected Kaposi's sarcoma patients. Science 268, 582-583 (1995)
76. Cornelissen M, Van Der Kuyl AC, van den Burg R, Zorgdrager F, Van Noesel CJ, Goudsmit J: Gene expression profile of AIDS-related Kaposi's sarcoma. BMC Cancer 3, 7 (2003).
77. McAllister SC, Hansen SG, Ruhl RA et al.: Kaposi sarcoma-associated herpesvirus (KSHV) induces heme oxygenase-1 expression and activity in KSHV-infected endothelial cells. Blood 103, 3465-3473 (2004).
78. Moses AV, Jarvis MA, Raggo C et al.: KSHV-induced upregulation of the c-Kit protooncogene, as identified by gene expresion profiling, is essential for the transformation of endothelial cells. J. Virol. 76, 8383-8399 (2002).
79. Poole LJ, Yu Y, Kim PS, Zheng QZ, Pevsner J, Hayward GS: Altered patterns of cellular gene expression in dermal microvascular endothelial cells infected with Kaposi's sarcoma-associated herpesvirus. J. Virol. 76, 3395-3420 (2002).
80. Hong YK, Foreman K, Shin JW et al.: Lymphatic reprogramming of blood vascular endothelium by Kaposi sarcoma-associated herpesvirus. Nat. Genet. 36, 683-685 (2004).
81. Pantanowitz L, Dezube BJ, Pinkus GS, Tahan SR: Histological characterization of regression in acquired immunodeficiency syndrome-related Kaposi's sarcoma. J. Cutan. Pathol. 31, 26-34 (2004).
82. Moses AV, Jarvis MA, Raggo C et al.: A functional genomics approach to Kaposi's sarcoma. Ann. NY Acad. Sci. 975, 180-191 (2002).
83. Tuveson DA, Willis NA, Jacks T et al.: STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene 20, 5054-5058 (2001).
84. Cools J, DeAngelo DJ, Gotlib J et al.: A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N. Engl. J. Med. 348, 1201-1214 (2003).
85. Rubin BP, Schuetze SM, Eary JF et al.: Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J. Clin. Oncol. 20, 3586-3591 (2002).
86. Cornali E, Zietz C, Benelli R et al.: Vascular endothelial growth factor regulates angiogenesis and vascular permeability in Kaposi's sarcoma. Am. J. Pathol. 149, 1851-1869 (1996).
87. Roth WK, Werner S, Schirren CG, Hofschneider PH: Depletion of PDGF from serum inhibits growth of AIDS-related and sporadic Kaposi's sarcoma cells in culture. Oncogene 4, 483-487 (1989).
88. Sturzl M, Brandstetter H, Zietz C et al.: Identification of interleukin-1 and platelet-derived growth factor-B as major mitogens for the spindle cells of Kaposi's sarcoma: a combined in vitro and in vivo analysis. Oncogene 10, 2007-2016 (1995).
89. Sturzl M, Roth WK, Brockmeyer NH, Zietz C, Speiser B, Hofschneider PH: Expression of platelet-derived growth factor and its receptor in AIDS-related Kaposi sarcoma in vivo suggests paracrine and autocrine mechanisms of tumor maintenance. Proc. Natl Acad. Sci. USA 89, 7046-7050 (1992).
90. Koon HB, Bubley GJ, Pantanowitz L et al.: Imatinib-induced regression of AIDS-related Kaposi's sarcoma. J. Clin. Oncol. 23, 982-989 (2004).
91. Choi AM, Alam J: Heme oxygenase-1: function, regulation, and implication of a novel stress-inducible protein in oxidant-induced lung injury. Am. J. Respir. Cell Mol. Biol. 15, 9-19 (1996).
92. Brouard S, Berberat PO, Tobiasch E, Seldon MP, Bach FH, Soares MP: Heme oxygenase-1-derived carbon monoxide requires the activation of transcription factor NF-κB to protect endothelial cells from tumor necrosis factor-α-mediated apoptosis. J. Biol. Chem. 277, 17950-17961 (2002).
93. Ke B, Buelow R, Shen XD et al.: Signaling by human herpesvirus 8 kaposin A through direct membrane recruitment of cytohesin-1. Mol. Cell. 7, 833-843 (2002).
94. Deramaudt BM, Braunstein S, Remy P, Abraham NG: Gene transfer of human heme oxygenase into coronary endothelial cells potentially promotes angiogenesis. J. Cell. Biochem. 68, 121-127 (1998).
95. Malaguarnera L, Pilastro MR, Quan S et al.: Significance of heme oxygenase in prolactin-mediated cell proliferation and angiogenesis in human endothelial cells. Int. J. Mol. Med. 10, 433-440 (2002).
96. Abdel-Aziz MT, El-Asmar MF, El-Miligy D et al.: Retrovirus-mediated human heme oxygenase-1 (HO-1) gene transfer into rat endothelial cells: the effect of HO-1 inducers on the expression of cytokines. Int. J. Biochem. Cell Biol. 35, 324-332 (2003).
97. Deramaudt BM, Remy P, Abraham NG: Upregulation of human heme oxygenase gene expression by Ets-family proteins. J. Cell. Biochem. 72, 311-321 (1999).
98. Suzuki M, Iso-o N, Takeshita S et al.: Facilitated angiogenesis induced by heme oxygenase-1 gene transfer in a rat model of hindlimb ischemia. Biochem. Biophys. Res. Commun. 302, 138-143 (2003).
99. Martinez JC, Garcia HO, Otheguy LE, Drummond GS, Kappas A: Control of severe hyperbilirubinemia in full-term newborns with the inhibitor of bilirubin production Sn-mesoporphyrin. Pediatrics 103, 1-5 (1999).
100. Valaes T, Drummond GS, Kappas A: Control of hyperbilirubinemia in glucose-6-phosphate dehydrogenase-deficient newborns using an inhibitor of bilirubin production, Sn-mesoporphyrin. Pediatrics 101, E1 (1998).
101. Raggo C, Ruhl R, McAllister S et al.: Novel cellular genes essential for transformation of endothelial cells by Kaposi's sarcoma-associated herpesvirus. Cancer Research (2005) (In press).
102. An J, Sun Y, Rettig MB: Transcriptional coactivation of c-Jun by the KSHV-encoded LANA. Blood 103, 222-228 (2004).
103. Godfrey A, Anderson J, Papanastasiou A, Takeuchi Y, Boshoff C: Inhibiting primary effusion lymphoma by lentiviral vectors encoding short hairpin RNA. Blood 105, 2516-2518 (1997).
104. Godfrey A, Laman H, Boshoff C: RNA interference: a potential tool against Kaposi's sarcoma-associated herpesvirus. Curr. Opin. Infect. Dis. 16, 593-600 (2003).
105. Zhu J, Trang P, Kim K, Zhou T, Deng H, Liu F: Effective inhibition of Rta expression and lytic replication of Kaposi's sarcoma-associated herpesvirus by human RNase P. Proc. Natl Acad. Sci. USA 101, 9073-9078 (2004).
106. Ensoli B, Nakamura S, Salahuddin SZ et al.: AIDS-Kaposi's sarcoma-derived cells express cytokines with autocrine and paracrine growth effects. Science 243, 223-226 (1989).
107. Masood R, Cai J, Zheng T, Smith DL, Naidu Y, Gill PS: Vascular endothelial growth factor/vascular permeability factor is an autocrine growth factor for AIDS-Kaposi sarcoma. Proc. Natl Acad. Sci. USA 94, 979-984 (1997).
108. Miles SA, Rezai AR, Salazar-Gonzalez JF et al.: AIDS Kaposi sarcoma-derived cells produce and respond to interleukin 6. Proc. Natl Acad. Sci. USA 87, 4068-4072 (1990).
109. Parkin DM, Bray F, Ferlay J, Pisani P: Estimating the world cancer burden: Globocan (2000). Int. J. Cancer. 94, 153-156 (2001).
110. Kliche S, Nagel W, Kremmer E et al.: Signaling by human herpesvirus 8 kaposin A through direct membrane recruitment of cytohesin-1. Mol. Cell 7, 833-843 (2001).